Paola Gazzaniga

Pubblicazioni

Titolo Pubblicato in Anno
Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer FRONTIERS IN ONCOLOGY 2023
Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer CELLS 2023
An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 2022
RAS mutation conversion in bevacizumab-treated metastatic colorectal cancer patients: a liquid biopsy based study CANCERS 2022
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation THE ONCOLOGIST 2022
Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study ONCOTARGET 2022
An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer FRONTIERS IN ONCOLOGY 2022
In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity CANCER DRUG RESISTANCE 2022
A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance inglese 2022
127P {RAS}, {RAF} and {NF}1 oncogenic mutations in {KRAS}-mutated lung adenocarcinoma ANNALS OF ONCOLOGY 2022
True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature CANCER LETTERS 2021
Sequential isolation and characterization of single CTCs and large CTC clusters in metastatic colorectal cancer patients CANCERS 2021
Comparison of two blood-based genotyping tests to investigate the KRAS G12C mutation in patients with non-small-cell lung cancer at failure of first-line treatments DIAGNOSTICS 2021
About RAS Mutation Clearance in Plasma ctDNA From RAS-Mutant Colorectal Cancer Patients JCO PRECISION ONCOLOGY 2021
3MO Oncogenic non-G12C {KRAS} mutations in {KRAS} G12C mutated lung adenocarcinomas in {TRACERx} and {GENIE}: A reservoir for intrinsic resistance to {KRAS} G12C inhibitors ANNALS OF ONCOLOGY 2021
Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights ONCOLOGY 2020
Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer ONCOTARGET 2020
Liquid Biopsy for Predicting Bacillus Calmette-Guérin Unresponsiveness in Non-muscle-invasive Bladder Cancer EUROPEAN UROLOGY ONCOLOGY 2020
Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients CANCERS 2020
Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. JOURNAL OF THE NATIONAL CANCER INSTITUTE 2020

ERC

  • LS4_12

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

liquid biopsy of cancer, circulating tumor DNA, circulating tumor cells

Keywords

liquid biopsy

Progetti di Ricerca

Laboratori di ricerca

BIOPSIA LIQUIDA LAB 01

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma